NASDAQ:TCON - TRACON Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.75
  • Forecasted Upside: 314.47 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.80
▲ +0.08 (2.15%)

This chart shows the closing price for TCON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TRACON Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCON

Analyst Price Target is $15.75
▲ +314.47% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for TRACON Pharmaceuticals in the last 3 months. The average price target is $15.75, with a high forecast of $24.00 and a low forecast of $12.00. The average price target represents a 314.47% upside from the last price of $3.80.

This chart shows the closing price for TCON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in TRACON Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021Alliance Global PartnersInitiated CoverageBuy$13.00High
4/16/2021BTIG ResearchUpgradeNeutral ➝ Buy$14.00High
4/1/2021JonestradingInitiated CoverageBuyLow
2/10/2021Maxim GroupInitiated CoverageBuy$24.00Low
12/4/2020HC WainwrightBoost Price TargetPositive ➝ Buy$7.00 ➝ $12.00High
9/17/2020HC WainwrightBoost Price TargetBuy$4.00 ➝ $7.00High
8/17/2020HC WainwrightReiterated RatingBuy$4.00High
4/24/2020HC WainwrightLower Price TargetBuy$6.00 ➝ $4.00Medium
3/10/2020HC WainwrightLower Price TargetBuy$13.00 ➝ $6.00High
2/28/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $13.00High
1/17/2020HC WainwrightReiterated RatingBuy$18.00Medium
12/23/2019HC WainwrightBoost Price TargetBuy$15.00 ➝ $18.00Medium
11/7/2019HC WainwrightReiterated RatingBuy$2.00High
8/29/2019HC WainwrightInitiated CoverageBuy$2.00High
4/12/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
3/1/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00High
12/26/2018BTIG ResearchLower Price TargetBuy$9.00Low
5/10/2018Needham & Company LLCLower Price TargetBuy$8.00High
6/13/2017Stifel NicolausLower Price TargetBuy ➝ Buy$14.00 ➝ $6.00High
1/5/2017Stifel NicolausReiterated RatingBuy$14.00N/A
1/3/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
12/21/2016Jefferies Financial GroupInitiated CoverageBuy$10.00N/A
10/5/2016Stifel NicolausReiterated RatingBuy$14.00N/A
8/19/2016BTIG ResearchInitiated CoverageBuy$15.00N/A
(Data available from 7/24/2016 forward)
TRACON Pharmaceuticals logo
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $3.80
Low: $3.51
High: $3.89

50 Day Range

MA: $6.12
Low: $3.72
High: $7.26

52 Week Range

Now: $3.80
Low: $1.55
High: $12.20

Volume

1,177,935 shs

Average Volume

337,379 shs

Market Capitalization

$58.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of TRACON Pharmaceuticals?

The following equities research analysts have issued reports on TRACON Pharmaceuticals in the last twelve months: Alliance Global Partners, BTIG Research, HC Wainwright, Jonestrading, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for TCON.

What is the current price target for TRACON Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for TRACON Pharmaceuticals in the last year. Their average twelve-month price target is $15.75, suggesting a possible upside of 314.5%. Maxim Group has the highest price target set, predicting TCON will reach $24.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for TRACON Pharmaceuticals in the next year.
View the latest price targets for TCON.

What is the current consensus analyst rating for TRACON Pharmaceuticals?

TRACON Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCON will outperform the market and that investors should add to their positions of TRACON Pharmaceuticals.
View the latest ratings for TCON.

What other companies compete with TRACON Pharmaceuticals?

How do I contact TRACON Pharmaceuticals' investor relations team?

TRACON Pharmaceuticals' physical mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company's listed phone number is 858-550-0780 and its investor relations email address is [email protected] The official website for TRACON Pharmaceuticals is www.traconpharma.com.